Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 158(1): 55-63, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19737231

RESUMO

Anti-retroviral treatment (ART) usually results in efficient control of virus replication and in immune reconstitution. Among potential adverse effects, impairment of immune responses in terms of CD4(+) T cell counts has been attributed to some ART regimens, as with didanosine-tenofovir. We studied the functional integrity of adaptive and innate immunity during didanosine-tenofovir-containing ART. Two groups of extensively pretreated patients completing at least 48 weeks of ART containing either lamivudine-didanosine (n = 21) or tenofovir-didanosine (n = 25) were identified. In addition to standard clinical immune and virological parameters, we performed a flow cytometric analysis of natural killer (NK) cells, of memory and naive CD4(+) T cells and of T cell receptor alphabeta(+) T cells co-expressing inhibitory NK receptors. Functional analysis consisted in specific and total interferon-gamma production by NK cells and of recall antigen proliferation of peripheral blood mononuclear cells. Comparable clinical immunological reconstitution and virological control were confirmed in the two groups of patients in the absence of clinically relevant adverse effects. The proportion of CD4(+)CD45RA(+) T cells and of functionally inhibited killer immunoglobulin-like receptor T cell receptor alphabeta(+) cells, the proliferation to recall antigens as well as NK cell phenotype and function as determined by interferon-gamma production in patients treated with tenofovir-didanosine were comparable to those treated with a different regimen. Thus, no differences in functional innate or adaptive immune reconstitution are detected in drug-experienced human immunodeficiency virus-infected patients on tenofovir-didanosine nucleoside reverse transcription inhibitor regimens.


Assuntos
Adenina/análogos & derivados , Didanosina/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1 , Organofosfonatos/uso terapêutico , Inibidores da Transcriptase Reversa/uso terapêutico , Linfócitos T/imunologia , Adenina/uso terapêutico , Adulto , Contagem de Linfócito CD4 , Proliferação de Células , Quimioterapia Combinada , Citometria de Fluxo , Imunofluorescência , Seguimentos , Infecções por HIV/imunologia , Humanos , Memória Imunológica , Imunofenotipagem , Interferon gama/imunologia , Células Matadoras Naturais/imunologia , Lamivudina/uso terapêutico , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Estatísticas não Paramétricas , Tenofovir
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA